TransMedics (TMDX) director receives 2,922 RSUs in equity grant

Rhea-AI Filing Summary

Gunderson Thomas J. reported acquisition or exercise transactions in this Form 4 filing.

TransMedics Group, Inc. director Thomas J. Gunderson received an equity award of 2,922 restricted stock units. These RSUs were granted at no cash cost and each unit represents the right to receive one share of common stock. Following this grant, he directly holds 6,981 shares and RSUs in total, reflecting routine, compensation-related ownership rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gunderson Thomas J.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,922	$0.00	--

Holdings After Transaction: Common Stock — 6,981 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 2,922 RSUs Grant price per unit: $0.0000 per share Holdings after grant: 6,981 shares/RSUs

3 metrics

RSU grant size 2,922 RSUs Equity award to director on 2026-05-20

Grant price per unit $0.0000 per share Stated transaction price for RSU grant

Holdings after grant 6,981 shares/RSUs Total direct position following the award

Key Terms

restricted stock units ("RSUs"), contingent right, grant, award, or other acquisition

3 terms

restricted stock units ("RSUs") financial

"Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock."

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gunderson Thomas J.

(Last) (First) (Middle)

C/O TRANSMEDICS GROUP, INC.

200 MINUTEMAN ROAD

(Street)

ANDOVER MASSACHUSETTS 01810

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TransMedics Group, Inc. [ TMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/20/2026		A		2,922(1)	A	$0	6,981	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of 2,922 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

	By: /s/ Gerardo Hernandez, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did TransMedics (TMDX) director Thomas Gunderson report?

Director Thomas J. Gunderson reported receiving 2,922 restricted stock units in TransMedics. This is a stock-based compensation grant rather than an open-market trade, increasing his direct equity-linked holdings in the company.

How many TransMedics (TMDX) shares and RSUs does Thomas Gunderson hold after this filing?

After the reported grant, Thomas Gunderson holds a total of 6,981 shares and restricted stock units. This figure combines his existing position with the newly awarded 2,922 RSUs disclosed in the Form 4.

What are the terms of the 2,922 RSUs granted to the TransMedics (TMDX) director?

The 2,922 units are restricted stock units, each representing a contingent right to receive one share of TransMedics common stock. They were granted at a stated price of $0.0000 per unit as part of equity compensation.

Does the TransMedics (TMDX) Form 4 show a stock purchase or sale by the director?

The Form 4 shows an acquisition through a grant or award, coded as “A,” not an open-market purchase or sale. It reflects compensation in RSUs rather than the director buying or selling shares in the market.

What does the RSU footnote in the TransMedics (TMDX) Form 4 explain?

The footnote explains that the 2,922 units are restricted stock units. Each RSU gives a contingent right to receive one share of TransMedics common stock, clarifying that these are equity awards rather than currently issued, freely tradable shares.